Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York.

Rhea-AI Summary

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York. The company's management will engage in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested investors and stakeholders can access both live and archived webcasts of the presentation through Absci's investor relations website at investors.absci.com.

Argus Session date unavailable

+25.16% session move Open Argus

Details

News Market Reaction – ABSI

The recorded move for ABSI in the trading session of this news was +25.16%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.

Absci management is scheduled to participate in a fireside chat on Wednesday, February 5^th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact
press@absci.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Absci (ABSI) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

Absci (ABSI) is scheduled to present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5th, 2025, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time).

How can investors watch Absci's (ABSI) Guggenheim Conference presentation?

Investors can watch both the live and archived webcast of Absci's presentation through the company's investor relations website at investors.absci.com.

What type of presentation will Absci (ABSI) give at the Guggenheim Biotech Conference?

Absci will participate in a fireside chat format presentation at the Guggenheim Securities SMID Cap Biotech Conference.

Where is the Guggenheim SMID Cap Biotech Conference featuring Absci (ABSI) being held?

The Guggenheim Securities SMID Cap Biotech Conference featuring Absci is being held in New York, NY.